Leflunomide Metabolite, Serum or Plasma 

2007460
copy
 

Copy Utility


emailprint
Example Reports
Low
Normal
Ordering Recommendation

Therapeutic monitoring and evaluating full elimination of the drug (eg, toxicity, pregnancy).

Mnemonic
LEFLUMETSP
Methodology

High Performance Liquid Chromatography/Mass Spectrometry

Performed

Sun, Wed, Fri

Reported

1-6 days

New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation

Timing of specimen collection: Predose (trough). Obtain specimen 12 - 24 hours after last dose.

Collect

Plain red. Also acceptable: Lavender (EDTA), pink (K2EDTA), green (sodium heparin), or gray (sodium fluoride).

Specimen Preparation

Separate from cells within 2 hours of draw. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.2 mL)

Storage/Transport Temperature

Refrigerated. Also acceptable: Room temperature or frozen.

Unacceptable Conditions

Whole blood. Potassium oxalate or separator tubes.

Remarks
Stability

Ambient: 7 days; Refrigerated: 17 days; Frozen: 90 days

Reference Interval
Therapeutic Range Greater than 40.000 µg/mL
Toxic Level Not well established.

Interpretive Data

Therapeutic and toxic ranges are not well established. Concentrations greater than 40.000 µg/mL tend to correlate with improved patient outcome. A proposed therapeutic range is 50.000 - 100.000 µg/mL. Adverse reactions to Leflunomide, such as diarrhea, hypertension, and liver toxicity, do not correlate well with serum drug concentrations. Leflunomide has a potential risk for teratogenesis. For women being treated with Leflunomide who desire to become pregnant, enhanced drug elimination should be performed until plasma teriflunomide concentrations are lower than 0.020 µg/mL on two separate tests taken at least 14 days apart.

Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note
Hotline History
N/A
CPT Codes

80299

Are you an ARUP Client? Click here for your pricing.
Components
Component Test Code* Component Chart Name LOINC
2007461 Leflunomide Metabolite, Serum/Plasma 44828-2
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Arava
  • Arava® (Leflunomide (Teriflunomide), Serum or Plasma)
  • leflunomide blood concentration
  • Teriflunomide
Leflunomide Metabolite, Serum or Plasma